The core problem is definitional. In proliferating cells—the fibroblasts, epithelial cells and immune cells that dominate peripheral senescence research—a senescent cell is anchored by one non-negotiable feature: stable cell-cycle arrest. Around that anchor, researchers layer complementary evidence such as elevated senescence-associated beta-galactosidase activity, DNA damage marked by gamma-H2AX foci, loss of the nuclear scaffold protein Lamin B1, upregulation of the cyclin-dependent kinase inhibitors p16INK4a and p21Waf1/Cip1, mitochondrial and lysosomal dysfunction, and the senescence-associated secretory phenotype, or SASP—a cocktail of inflammatory cytokines, growth factors and proteases. Post-mitotic neurons, however, have already exited the cell cycle permanently. There is no arrest to observe, which strips senescence research of its single most reliable criterion and forces scientists to assemble the diagnosis from fragments that overlap poorly across studies.

The review highlights how this plays out in practice. In one influential long-term culture model, prenatal rat cortical neurons maintained for weeks in a dish began expressing p21Waf1/Cip1 and forming DNA damage foci by day 26 in vitro, accumulated lipofuscin, and showed impaired autophagic flux—yet the cultures’ cytokine profile diverged sharply from the canonical inflammatory SASP, with MCP-1 rising while IL-1, IL-6 and TNF-alpha stayed flat. Primary rat hippocampal neurons aged in culture told a different story again: they lost Lamin B1, reorganized their chromatin, activated p38 MAPK signaling and secreted CXCL-1, but did so without detectable DNA double-strand breaks or p21 induction. Intriguingly, these aged neurons also became more stress-resilient, boosting the pro-survival factor Bcl-2 and suppressing the pro-apoptotic protein Puma, hinting that what looks like senescence in a neuron might partly serve a protective function under chronic stress.

The clearest evidence that non-dividing neurons can acquire senescence-like features in living brains came from studies of naturally aged mice. In aged C57BL/6 animals, Purkinje and cortical neurons accumulated DNA damage, activated p38 MAPK, deposited lipofuscin, increased the lipid peroxidation marker 4-hydroxynonenal and raised IL-6 production, while cortical neurons showed deposition of the histone variant macroH2A—a signature of the senescence-associated chromatin remodeling seen in dividing cells. Genetic experiments added mechanistic depth: deleting CDKN1A, the gene encoding p21, blunted several senescence markers, while loss of telomerase drove telomere dysfunction and stronger inflammatory signaling in a p21-dependent manner. Mild dietary restriction reduced the senescence-associated burden in Purkinje cells, suggesting that even in post-mitotic neurons, the senescence program is regulable.

Where the story turns urgently clinical is in neurodegeneration. In Alzheimer’s disease models, amyloid-beta oligomers pushed hippocampal neural progenitor cells into a senescence-like state that impaired neurogenesis, acting through the formylpeptide receptor 2 and a ROS–p38 MAPK pathway. More striking still, work with directly converted induced neurons—fibroblasts from Alzheimer’s patients reprogrammed into cortical neurons without erasing their age signatures—revealed a neuron-specific senescence and inflammation program, including CDKN2A upregulation and accessible SASP gene promoters, that was absent from rejuvenated induced pluripotent stem cell-derived neurons. Conditioned medium from these senescent Alzheimer’s neurons activated astrocytes into a reactive, senescence-associated state, and treatment with the senolytic drugs dasatinib and quercetin reduced the proportion of senescent neurons back to control levels.

Tau pathology strengthened the link further. In transgenic mice carrying mutant human tau, neurofibrillary tangle formation coincided with elevated gamma-H2AX, CDKN2A, CDKN1A and up to thirteen-fold increases in SASP-associated factors, along with mitochondrial dysfunction confined to tau-affected regions. Removing the tau transgene reversed the burden, and senolytic treatment increased neuron-specific proteins, improved cerebral blood flow and reduced neurodegeneration. In a sweeping analysis of 76 human post-mortem brains, more than 97 percent of cells showing a senescence-like phenotype—altered morphology, lipofuscin accumulation and p19 expression—turned out to be excitatory neurons, and those cells spatially overlapped with neurofibrillary tangles. The implication is provocative: senescent-like neurons may be woven directly into the fabric of tau-driven degeneration rather than standing apart from it.

Parkinson’s disease research tells a parallel but distinct tale. Depleting the chromatin-binding protein SATB1, recently identified as a Parkinson’s-linked factor, triggered a senescence-like phenotype selectively in dopaminergic neurons—involving p21 upregulation, Lamin B1 loss, lysosomal dysfunction and reactive oxygen species—while leaving cortical neurons largely unaffected. SATB1 normally represses p21 by binding the CDKN1A regulatory region, and its loss in mouse midbrain and post-mortem Parkinson’s tissue confirmed p21-linked neuronal changes accompanied by microglial activation. Meanwhile, alpha-synuclein pathology, modeled with pre-formed fibrils or overexpression, produced senescence-like changes that varied dramatically by cell type: neurons showed limited or transient marker shifts, while astrocytes and microglia mounted stronger senescence responses. In A53T alpha-synuclein mice, senescence markers surged within a week of overexpression—before any dopaminergic neuron loss or motor impairment—raising the possibility that senescence is an early pathogenic event rather than a downstream consequence. Iron overload amplified these phenotypes, and iron chelation with deferoxamine blunted them, pointing toward iron homeostasis as a druggable node.

Yet the review’s central message is caution. The marker combinations used to label neurons as senescent vary so widely across studies that two labs can reach opposite conclusions about the same phenomenon. p16INK4a immunostaining, a staple of peripheral senescence work, is notoriously unreliable in brain tissue because of its low baseline expression and antibody-specificity problems. Toxin-based studies often rely on immortalized cell lines such as SH-SY5Y, N27 and PC12, whose proliferative origin makes their stress responses poor proxies for mature neuronal aging. And senescence-like glial and vascular phenotypes—well documented in astrocytes and brain endothelial cells, where senolytic clearance restores blood-brain barrier integrity and cognitive function in mice—may dominate the senescence landscape of the diseased brain, with neurons affected more indirectly than the field has often assumed.

The authors argue that the solution lies in building neuron-centered senescence frameworks from the ground up. Single-nucleus RNA sequencing, spatial transcriptomics and proteomics are beginning to map cell-type-specific aging trajectories in human cortex, revealing mosaic senescence signatures that only partially overlap with canonical peripheral panels. The goal is a standardized, multi-parametric marker set—integrating DNA damage, chromatin state, lysosomal and mitochondrial function, and context-specific SASP factors—validated across cultures, animal models and human tissue. Such a framework would finally allow researchers to answer the field’s biggest open question: whether senescent neurons are a primary driver of neurodegeneration, or a context-dependent catalyst that lowers the brain’s resilience and amplifies damage set in motion by proteinopathies. Either way, the stakes are high, because senolytic and SASP-targeting drugs are already advancing toward the clinic, and knowing precisely which cells to target—and when—could determine whether the senescence revolution extends from the body to the brain.

Subject of Research: Cellular senescence in post-mitotic neurons during brain aging and neurodegenerative disease

Article Title: Rethinking Senescence Hallmarks in the Brain: Lessons From Peripheral Tissues and Challenges in Defining Neuronal Senescence

Article References: Momand, M. U. D., Macova, K., & Fricova, D. (2026). Rethinking Senescence Hallmarks in the Brain: Lessons From Peripheral Tissues and Challenges in Defining Neuronal Senescence. Aging Cell, 25(9), Article e70719. https://doi.org/10.1111/acel.70719

Image Credits: AI Generated

DOI: 10.1111/acel.70719

Keywords: cellular senescence, neurons, brain aging, Alzheimer's disease, Parkinson's disease, SASP, senolytics, p16INK4a, p21, tau pathology, alpha-synuclein, neurodegeneration

The research, led by Hyman B. Muss of the University of North Carolina at Chapel Hill and Mina S. Sedrak of UCLA, together with colleagues at City of Hope and the Mayo Clinic, examined 251 women with early-stage breast cancer and 49 cancer-free controls. The team measured p16INK4a, a gene whose expression rises as cells enter senescence—a state of permanent growth arrest linked to aging and disease—and compared it against five DNA methylation clocks: Horvath, Hannum, PhenoAge, GrimAge, and the Dunedin Pace of Aging, known as mPoA. DNA methylation clocks estimate biological age from characteristic patterns of chemical tags on DNA that shift predictably over a lifetime.

The two biomarker families barely spoke to each other. Across both cancer patients and controls, correlations between T-cell p16 and the methylation clocks were weak, with correlation coefficients generally below 0.3. In the cancer cohort, p16 showed only modest associations with Hannum, PhenoAge, and GrimAge, and none at all with the Horvath clock or the Dunedin pace measure. The pattern held in the control group and in a separate cohort of younger patients, where the strongest relationship—between p16 and GrimAge—reached only a moderate correlation of 0.40. The Dunedin measure, which estimates the rate of aging rather than accumulated age, showed essentially no relationship with p16 anywhere.

That disconnect matters because researchers and clinicians increasingly rely on these tests to gauge whether diseases or treatments are accelerating aging, and to evaluate interventions meant to slow it down. If p16 and methylation clocks captured the same underlying biology, they could be used interchangeably. The new findings suggest they cannot. The authors argue that the two measures reflect fundamentally different aspects of aging: p16 tracks senescence within a specific immune cell population, while methylation clocks integrate epigenetic signals across the heterogeneous mixture of cell types found in whole blood. Differences in biological compartment, measurement scale, and clock design—all calibrated differently, some to chronological age and others to mortality risk—likely all contribute to the weak overlap.

The study also probed whether cancer itself leaves a measurable imprint on these markers. When the researchers plotted biomarker levels against chronological age, women with breast cancer did not differ from controls in p16, Hannum, Horvath, or the Dunedin pace measure. But two of the mortality-informed clocks told a different story: GrimAge and PhenoAge were both significantly higher in the cancer group, and the differences persisted after adjusting for race, ethnicity, and body mass index. The result aligns with a growing body of evidence that cancer is associated with physiological changes consistent with accelerated aging, while suggesting that standard epigenetic clocks are not uniformly sensitive to that signal.

The most striking results came from the longitudinal arm. In a subset of 48 women with early breast cancer who gave blood before and three to six months after adjuvant chemotherapy, p16 expression rose significantly, by an average of 0.7 log2 units—an increase the authors note is equivalent to roughly 10 to 20 years of chronological aging. Yet four of the five methylation clocks—Horvath, PhenoAge, GrimAge, and the Dunedin pace—showed no significant change over the same interval. Only the Hannum clock increased, and only modestly. When the team split patients into those whose p16 rose beyond assay precision and those whose did not, none of the epigenetic clocks changed in either group, underscoring that the chemotherapy signal seen in senescence markers simply was not mirrored in the methylation-based measures.

The findings complicate the interpretation of earlier studies. Some prior work reported epigenetic age acceleration after cancer treatment: one study of breast cancer survivors found those who received chemotherapy were biologically two to three years older than controls two to three years after treatment, and a small study of 18 patients reported acceleration of roughly 3.5 to 8 years after a single anthracycline-containing cycle, though that analysis lacked paired samples. Other research found clock changes only years or decades later, or no change at all depending on regimen and follow-up timing. The new data suggest methylation clocks are not blind to treatment-related aging effects, but may respond on a different timescale or capture different biological consequences than the rapid senescence response registered by p16.

The team also explored senescence-associated secretory phenotype proteins—inflammatory molecules shed by senescent cells that have been linked to morbidity and mortality. In 20 patients treated with doxorubicin-based chemotherapy, chemotherapy-induced increases in p16 correlated with rising levels of PARC, TNFRII, ICAM1, and TNF-alpha. Intriguingly, baseline p16 showed little to no association with baseline levels of these proteins, suggesting the link is driven by the chemotherapy itself. Together with prior work showing increased p16, DNA damage, and inflammatory markers in survivors over two years, the results paint a picture in which cytotoxic chemotherapy provokes a coordinated senescence and inflammatory response that current epigenetic clocks largely miss.

The authors are careful about the limits of their analysis. The longitudinal component was exploratory and small; the cross-sectional and longitudinal cohorts differed in age and sampling protocols; p16 and methylation were measured in different biological compartments; and chemotherapy-related shifts in immune cell composition can confound whole-blood methylation measures. The three-to-six-month follow-up window may also simply be too short for clocks that evolve over years. Treatment regimens were heterogeneous, mixing anthracycline and non-anthracycline approaches, though recent long-term follow-up found persistently elevated p16 regardless of regimen.

Even so, the message is clear and potentially consequential: the most popular biomarkers of biological aging are not interchangeable. Choosing between them requires knowing which aging process—and which timescale—a study actually cares about. For the millions of breast cancer survivors living with the long-term consequences of treatment, that distinction could shape how researchers track accelerated aging, design interventions such as exercise or senolytic drugs, and ultimately judge whether a therapy that cures cancer is also quietly aging the body that carries it.

Subject of Research: Comparison of cellular senescence marker p16INK4a and DNA methylation epigenetic clocks as biomarkers of biological aging in women with early breast cancer treated with chemotherapy

Article Title: p16INK4a and DNA methylation clocks in women treated with chemotherapy for early breast cancer

Article References: p16INK4a and DNA methylation clocks in women treated with chemotherapy for early breast cancer. (n.d.). https://doi.org/10.1007/s11357-026-02521-3

Image Credits: AI Generated

DOI: 10.1007/s11357-026-02521-3

Keywords: p16INK4a, DNA methylation clocks, biological aging, cellular senescence, breast cancer, chemotherapy, epigenetic age, GeroScience, GrimAge, PhenoAge, biomarkers of aging, cancer survivors

The research focused on cellular senescence, a state of stable cell cycle arrest triggered by replicative exhaustion, DNA damage, or oxidative stress. Senescent cells are not dead. They remain metabolically active, resist apoptosis, and release a potent cocktail of cytokines, chemokines, growth factors, and matrix-remodeling enzymes known as the senescence-associated secretory phenotype, or SASP. This secretory program is widely believed to drive the chronic, low-grade, sterile inflammation called inflammaging, a hallmark of aging tissues. In the kidney, the cyclin-dependent kinase inhibitor p16Ink4a, encoded by the Cdkn2a gene, serves as one of the most reliable markers of senescence, and its ablation has previously been shown to improve repair after ischemic injury and extend graft survival.

To dissect the relationship between senescent cells and immune cells, the team combined quantitative histology, RNA in situ hybridization for Cdkn2a, NanoString-based transcriptomics of fibrosis and inflammation gene panels, and Visium spatial transcriptomics. They worked with young mice aged three to four months and old mice aged 22 to 24 months on a C57BL/6J background, and their first key observation was one of remarkable heterogeneity. Although Cdkn2a expression was significantly elevated in aged kidneys overall, individual old animals varied enormously. When the researchers stratified old mice into p16-low and p16-high groups, they found that the p16 signal, rather than chronological age, was the strongest predictor of the inflammatory transcriptome, associating with 60 significantly regulated genes involved in cytokine signaling, chemotaxis, and antigen presentation.

Immunostaining confirmed that aging remodels the kidney’s immune landscape. Old kidneys contained significantly more CD45-positive leukocytes, F4/80-positive macrophages, and CD3-positive T cells than young ones, and even rarer populations such as CD138-positive plasma cells and NKp46-positive natural killer cells increased with age. Activated macrophage phenotypes, both pro-inflammatory CD86-positive and pro-fibrotic CD206-positive cells, also rose. But when old kidneys were separated by senescence burden, macrophages stood out as the population most tightly linked to p16 levels, being significantly more abundant in p16-high kidneys, while T cells, plasma cells, and NK cells showed no significant differences between the groups.

The study’s most visually compelling finding came from its spatial analyses. Using senescence-associated beta-galactosidase staining merged with immunofluorescence, and separately using high-resolution RNAscope detection of Cdkn2a transcripts combined with immune markers, the researchers demonstrated that both leukocytes and macrophages were significantly enriched in immediate proximity to senescent tubular structures. The immune cells were not themselves senescent; they clustered around p16-positive tubules like moths around a lamp. Notably, p16 expression was predominantly localized to tubular epithelial cells, with interstitial p16-positive cells being rare and explicitly excluded from the colocalization analysis, addressing the known caveat that macrophages can express p16 independently of senescence.

Supplementary Visium spatial transcriptomics independently reinforced this picture. By integrating the team’s own pilot data with a public mouse kidney dataset, the analysis revealed a cortex-restricted transcriptomic cluster that combined senescence-associated genes such as Cdkn1a, Trp53, Serpine1, Tgfb1, and Ccl2 with immune-associated signatures and a prominent macrophage component. The same cluster also expressed markers of failed-repair proximal tubules, including Havcr1, which encodes kidney injury molecule 1, along with Vcam1 and C3. This convergence of senescence, inflammation, and maladaptive repair signaling within a single spatial neighborhood provides strong evidence that the aging kidney cortex hosts organized inflammatory niches rather than a diffuse, uniform inflammatory haze.

The researchers then asked whether these niches are modifiable. They applied two senolytic strategies: pharmacological clearance using the BCL-2/BCL-xL inhibitor ABT-737 in old mice aged 20 to 22 months, and genetic ablation in middle-aged INK-ATTAC mice, in which administration of AP20187 inducibly kills p16-expressing cells. Both interventions significantly reduced the Cdkn2a signal, and histological analysis showed decreased infiltration of both leukocytes and macrophages in treated kidneys. Critically, colocalization analysis revealed that in vehicle-treated controls, immune cells clustered strongly around senescent cells, whereas after ABT-737 treatment this spatial relationship largely dissolved for leukocytes, which became distributed more evenly throughout the tissue.

One nuance deserves emphasis. Even after senolysis, macrophages remained preferentially enriched near the residual senescent tubules, although their overall numbers fell. The authors propose several explanations: remaining senescent cells may continue to emit chemokine signals, particularly through the Ccl2-Ccr2 axis, which is known to recruit Ccr2-positive myeloid cells during senescence surveillance; macrophages may persist locally as tissue-resident cleaners of damaged cells; or altered immune cell turnover may shape the residual pattern. The p16-high kidneys in the cohort also showed increased Ccr2 expression together with macrophage-associated gene signatures, consistent with this recruitment model. Distinguishing between persistent recruitment, local retention, and altered turnover will require future work.

The findings carry broader implications for how scientists conceptualize biological aging. Because the p16-high and p16-low old mice were genetically identical and chronologically matched, the divergence in inflammatory profiles reflects differences in biological rather than chronological aging. This supports the idea that senescence burden is a more faithful indicator of renal inflammatory remodeling than age itself, echoing previous observations of variable senescence signatures in aging human kidneys. The study also suggests that the inflammatory microenvironments of renal aging are at least partially reversible, and that intervening at middle age, before senescence burden fully accumulates, can already blunt immune cell accumulation, hinting at a preventive window for senolytic therapies.

The authors are candid about limitations. Both senolytic approaches act systemically rather than specifically on renal tubular cells, so the observed reduction in inflammation cannot be attributed exclusively to clearing senescent tubules; ABT-737 also carries known hematologic off-target effects, which is why the genetic models were included as complementary evidence. The short observation period after treatment precludes conclusions about long-term durability, the bulk transcriptomic data cannot assign gene expression to individual cell types, and differences between murine and human immune systems may limit direct translation. Nevertheless, by mapping senescence and immunity with spatial precision, the study provides a framework in which senescent tubular structures serve as nucleation sites for inflammaging in the kidney, and it positions these senescence-associated inflammatory niches as concrete, targetable structures for future therapies against renal aging and chronic kidney disease.

Subject of Research: Spatial organization of senescent cell and immune cell interactions in the aging mouse kidney and their modulation by senolytic therapy

Article Title: Insights Into the Interplay Between the Senescent Cells and Immune Cells

Article References: Jaros, M., Schmidt, M., Neubert, L., Kamp, J.-C., von Vietinghoff, S., Bräsen, J. H., Schmitt, R., & Melk, A. (2026). Insights Into the Interplay Between the Senescent Cells and Immune Cells. Aging Cell, 25(9), Article e70698. https://doi.org/10.1111/acel.70698

Image Credits: AI Generated

DOI: 10.1111/acel.70698

Keywords: cellular senescence, kidney aging, p16Ink4a, macrophages, inflammaging, SASP, senolytics, ABT-737, INK-ATTAC, spatial transcriptomics, chronic kidney disease, renal cortex